Found a way to help families & local shops! I’m donating $150 today for gift cards to families in shelters- the team Building Impact is delivering to each family. Join me by donating & writing in the recipient as “Family Aid with Mike”. Let’s do this! buildingimpact.org/familyaid-bost…

It takes a long time and many people to develop new drugs and get them approved, and members of the disease community often play a critical role. That was certainly the case for our recently approved treatment for adults with acute hepatic #porphyria. This is that story. #RNAi

Such an important and timely interview with Tony Coles, MD by Adam Feuerstein ✡️ Damian Garde and Rebecca Robbins! “It’s just a question of humanity at the end of the day.“ statnews.com/2020/06/05/ton…

Today, for the first time, we shared full results from the Phase 3 ILLUMINATE-A pivotal study of lumasiran, our investigational #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1) at the #ERAEDTA20 virtual congress. #nephrology @ERAEDTA #raredisease

In a new post, our Chief Early Development Officer shares his perspective on why seamless integration across groups within R&D is SO critical to the prospects for future success in #drugdevelopment & how creation of a new R&D structure helped turbo-charge our discovery efforts.

Barry Greene, Alnylam Pharmaceuticals, Desiree Lyon, American Porphyria Foundation and Pablo Graiver, IQVIA will discuss Partnering with Advocacy to Help Patients with Clinical Trial Enrollment and Access to Treatments on Aug 19th at Patients as Partners - bit.ly/3g5FklI #PatientsasPartners

Last night, Russia launched a brazen attack on the people of Ukraine, in violation of international law and basic principles of human decency. Here’s my statement on what it means, and what should happen next.

Yesterday, we gathered at MIT and remotely around the world for our Founders Day which featured talks by leadership and a lively panel discussion w/ founders and others instrumental in the birth of Alnylam 20 years ago. #RNAiRevolution #Alnylam20th #RNAi #RNAitherapeutics #siRNA

We’re thrilled to share the news that we have received U.S. FDA approval for AMVUTTRA (vutrisiran), the fifth #RNAi therapeutic developed by Alnyam to receive regulatory approval in less than four years. #raredisease #biotech #RNAitherapeutics #siRNA

Really enjoyed spending time with some former Alnylam Pharmaceuticals colleagues advancing new frontiers of science and medicine for patients! These are very exciting times!

We are thrilled to be sharing the official launch of Aera Therapeutics, a company aiming to help broaden the reach of genetic medicines! I’m excited to embarking on this journey with such an incredible team of scientists, investors, and board members!

Congratulations to the Intellia team, and in particular to good friends and former colleagues Laura Sepp-Lorenzino and Jim Butler! Great news for the field and #hereditaryangioedema patients!

Great colleagues and great people!

Our team had a colorful celebration for #PrideMonth by wearing different shades of the #PrideFlag.🏳️‍🌈We enjoyed our time coming together as a company and recognizing the LGBTQ+ community. Happy Pride from Aera!

We're excited to be building the lab of the future! Come see the build in process on BiotechTV !

Thank you to David Schenkein and Issi Rozen and the rest of the GV for hosting the conversation!

It is an honor to be selected Startup of the Year by Biotech Week Boston in recognition of our mission to develop transformative #geneticmedicines. Our CEO, Akin Akinc, received the award at #BWBAwards 2023 last night. Congrats to all winners & nominees! informaconnect.com/bwb-awards/awa…

We are thrilled to be named by Endpoints News as a 2023 #endpts11 winner in recognition of our mission to harness enabling delivery technologies to develop transformative #geneticmedicines! Thank you to the Aera team for your unwavering commitment. endpts.com/the-endpoints-…

It was a pleasure to be @ Benchtalk 2024 this week where our own Samivel Evans received the inaugural Benchling Champion award. Additional thanks to Brad Loncar & @BiotechTVHQ for a great discussion w/ our VP, Computation and Lab Technology, Bob Gantzer. biotechtv.com/post/bob-gantz…